The 2025 SEMALEAN study, which tracked 106 patients on semaglutide 2.4 mg using DXA body composition scans over 12 months, confirmed that semaglutide does cause some lean mass loss alongside fat loss a pattern seen with virtually all significant caloric restriction
Semaglutide works by building up in your bloodstream over days, creating steady appetite control through GLP-1 receptor activation
The metabolic improvements associated with GLP-1 agonist use, including better glucose control and weight management, may indirectly contribute to improved brain health
For these individuals, the pill format and dosing freedom removes significant practical and psychological barriers to entry
Instead of escalating dosages on an arbitrary schedule, our physician-designed protocol increases or decreases doses based on a members evolving progress and side effects
Your doctor will monitor your kidney function through blood and urine tests